Pitfalling in nanomedical targeting of melanoma: a ‘clinical’ case of misdelivered RNAi

This publication has 12 references indexed in Scilit:

• Aberrant Expression of TfR1/CD71 in Thyroid Carcinomas Identifies a Novel Potential Diagnostic Marker and Therapeutic Target
  Thyroid®, 2011
• Delivering nanomedicine to solid tumors
  Nature Reviews Clinical Oncology, 2010
• Strategies in the design of nanoparticles for therapeutic applications
  Nature Reviews Drug Discovery, 2010
• Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
  Nature, 2010
• Targeting Hypoxia-inducible Factor-1α With Tf–PEI–shRNA Complex via Transferrin Receptor–mediated Endocytosis Inhibits Melanoma Growth
  Molecular Therapy, 2009
• Nanoparticle therapeutics: an emerging treatment modality for cancer
  Nature Reviews Drug Discovery, 2008
• Tumor-targeted Delivery of siRNA by Self-assembled Nanoparticles
  Molecular Therapy, 2008
• Transferrin receptor 2 is frequently expressed in human cancer cell lines
  Blood Cells, Molecules, and Diseases, 2007
• The transferrin receptor part II: Targeted delivery of therapeutic agents into cancer cells
  Clinical Immunology, 2006
• In situ analysis of antigens on malignant and benign cells of the melanocyte lineage. Differential expression of two surface molecules, gp75 and p89.
  Journal of Experimental Medicine, 1985